로딩 중…
지수 로딩 중…
REGENXBIO Inc.
RGNX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$9.96+2.79%
2026-08-03
Financials
Valuation Metrics
REGENXBIO Inc.'s Market Cap is $515M. At end of 2025 it was $745M. Ranked #2794 of 3,111 in US market (top 90%), #1217 of 1,445 on NASDAQ (top 84%), #226 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $515M | US#2,794/3,111 Sec#226/269 |
| Revenue | $88M | US#2,813/3,111 Sec#132/269 |
| Net Income | $-290M | US—/3,111 Sec—/269 |
| Total Assets | $342M | US#2,874/3,111 Sec#198/269 |
| Net Assets | $161M | US#2,800/3,111 Sec#212/269 |
| Value | ||
| P/B | 3.19x | US#1,735/3,111 Sec#92/269 |
| P/S | 5.86x | US#2,366/3,111 Sec#91/269 |
| FCF Yield | -45.91% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -179.63% | US#2,906/3,111 Sec#234/269 |
| ROA | -84.83% | US#3,045/3,111 Sec#259/269 |
| Op. Margin | -292.28% | US#2,884/3,111 Sec#151/269 |
| Revenue Growth | -92.82% | US#2,940/3,111 Sec#183/269 |
| Earnings Growth | -1580.37% | US#2,379/3,111 Sec#95/269 |
| Financial Health | ||
| Debt Ratio | 198.70% | US#1,790/3,111 Sec#203/269 |
| Total Debt | $71M | US#2,503/3,111 Sec#140/269 |
| FCF | $-236M | US#2,762/3,111 Sec#227/269 |
| Cash | $15M | US#2,915/3,111 Sec#265/269 |
| Current Ratio | 2.62x | US#950/3,111 Sec#207/269 |
| Performance | ||
| 1Y Return | 21.61% | US#1,603/3,111 Sec#175/269 |
| 1M Return | -25.00% | US#2,948/3,111 Sec#253/269 |
| From 52W High | -38.48% | US#2,485/3,111 Sec#194/269 |
| 1Y MDD | -64.64% | US#2,821/3,111 Sec#230/269 |
| Trading | ||
| Volume | 796,520 shares | US#1,314/3,111 Sec#126/269 |
| Trading Value | $8M | US#2,227/3,111 Sec#179/269 |
| Per Share | ||
| EPS | $-3.75 | US—/3,111 Sec—/269 |
| BPS | $1.99 | US#2,512/3,111 Sec#178/269 |